Header Logo

Connection

HANA EL SAHLY to Adult

Back to Details
This is a "connection" page, showing publications HANA EL SAHLY has written about Adult.
HANA EL SAHLY
Connection Strength
0.456
Adult
  1. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021 Nov 04; 385(19):1774-1785.
    View in: PubMed
    Score: 0.032
  2. The Reply. Am J Med. 2019 08; 132(8):e668.
    View in: PubMed
    Score: 0.027
  3. Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. Vaccine. 2019 05 01; 37(19):2561-2568.
    View in: PubMed
    Score: 0.027
  4. Vaccination in the Adult Patient Infected with HIV: A Review of Vaccine Efficacy and Immunogenicity. Am J Med. 2019 04; 132(4):437-446.
    View in: PubMed
    Score: 0.027
  5. Survival of an AIDS patient after infection with Acanthamoeba sp. of the central nervous system. Infection. 2017 Oct; 45(5):715-718.
    View in: PubMed
    Score: 0.024
  6. Mycobacterium tuberculosis bacteraemia: experience from a non-endemic urban centre. Clin Microbiol Infect. 2014 Mar; 20(3):263-8.
    View in: PubMed
    Score: 0.018
  7. Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. J Infect Dis. 2012 Mar 01; 205(5):703-12.
    View in: PubMed
    Score: 0.016
  8. Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas. J Clin Microbiol. 2011 Aug; 49(8):2942-5.
    View in: PubMed
    Score: 0.016
  9. Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic. Clin Vaccine Immunol. 2010 Oct; 17(10):1552-9.
    View in: PubMed
    Score: 0.015
  10. Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. Vaccine. 2009 Aug 06; 27(36):4905-11.
    View in: PubMed
    Score: 0.014
  11. Pandemic H5N1 influenza vaccine development: an update. Expert Rev Vaccines. 2008 Mar; 7(2):241-7.
    View in: PubMed
    Score: 0.013
  12. Recurrent tuberculosis in Houston, Texas: a population-based study. Int J Tuberc Lung Dis. 2004 Mar; 8(3):333-40.
    View in: PubMed
    Score: 0.010
  13. The effect of mannose binding lectin gene polymorphisms on susceptibility to tuberculosis in different ethnic groups. Scand J Infect Dis. 2004; 36(2):106-8.
    View in: PubMed
    Score: 0.009
  14. Identification of immunodominant T cell epitopes induced by natural Zika virus infection. Front Immunol. 2023; 14:1247876.
    View in: PubMed
    Score: 0.009
  15. Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials. JAMA Netw Open. 2023 Jul 03; 6(7):e2323349.
    View in: PubMed
    Score: 0.009
  16. Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials. Vaccine. 2023 07 25; 41(33):4899-4906.
    View in: PubMed
    Score: 0.009
  17. Persistence of Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Healthy Adults: 2 Years of Follow-up Compared With Natural Infection. J Infect Dis. 2023 05 29; 227(11):1303-1312.
    View in: PubMed
    Score: 0.009
  18. Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE Trials. Clin Infect Dis. 2023 01 13; 76(2):271-280.
    View in: PubMed
    Score: 0.009
  19. Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial. Lancet Infect Dis. 2023 04; 23(4):484-495.
    View in: PubMed
    Score: 0.009
  20. Mycobacterium simiae pseudo-outbreak resulting from a contaminated hospital water supply in Houston, Texas. Clin Infect Dis. 2002 Oct 01; 35(7):802-7.
    View in: PubMed
    Score: 0.009
  21. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022 09; 10(9):888-899.
    View in: PubMed
    Score: 0.008
  22. Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med. 2022 03 17; 386(11):1046-1057.
    View in: PubMed
    Score: 0.008
  23. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022 Jan 07; 375(6576):43-50.
    View in: PubMed
    Score: 0.008
  24. Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease. Clin Infect Dis. 2021 04 08; 72(7):1127-1137.
    View in: PubMed
    Score: 0.008
  25. Sensitive and Prolonged Detection of Dengue Virus RNA in Whole Blood. Am J Trop Med Hyg. 2021 03 22; 104(5):1734-1736.
    View in: PubMed
    Score: 0.008
  26. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 02 04; 384(5):403-416.
    View in: PubMed
    Score: 0.008
  27. Epidemiologic differences between United States- and foreign-born tuberculosis patients in Houston, Texas. J Infect Dis. 2001 Feb 01; 183(3):461-8.
    View in: PubMed
    Score: 0.008
  28. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 03 04; 384(9):795-807.
    View in: PubMed
    Score: 0.008
  29. A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area. Vaccine. 2019 10 08; 37(43):6500-6509.
    View in: PubMed
    Score: 0.007
  30. Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial. Vaccine. 2017 08 24; 35(36):4730-4737.
    View in: PubMed
    Score: 0.006
  31. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. Vaccine. 2017 03 23; 35(13):1675-1682.
    View in: PubMed
    Score: 0.006
  32. Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial. Vaccine. 2017 02 07; 35(6):923-928.
    View in: PubMed
    Score: 0.006
  33. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015 Jul 21; 314(3):237-46.
    View in: PubMed
    Score: 0.005
  34. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-na?ve subjects. Vaccine. 2015 Sep 22; 33(39):5225-34.
    View in: PubMed
    Score: 0.005
  35. Mycobacterium avium complex-associated cholecystitis in AIDS patient: a case description and review of literature. Int J STD AIDS. 2016 11; 27(13):1218-1222.
    View in: PubMed
    Score: 0.005
  36. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine. 2015 Jan 01; 33(1):163-73.
    View in: PubMed
    Score: 0.005
  37. Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults. Vaccine. 2014 Oct 29; 32(47):6284-93.
    View in: PubMed
    Score: 0.005
  38. Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial. Vaccine. 2014 Feb 12; 32(8):1019-28.
    View in: PubMed
    Score: 0.005
  39. Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis. 2012 Oct 01; 206(7):1069-77.
    View in: PubMed
    Score: 0.004
  40. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok?) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine. 2011 Oct 13; 29(44):7733-9.
    View in: PubMed
    Score: 0.004
  41. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine. 2011 Oct 06; 29(43):7357-63.
    View in: PubMed
    Score: 0.004
  42. A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine. 2010 Apr 09; 28(17):3025-9.
    View in: PubMed
    Score: 0.004
  43. Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults. Hum Vaccin. 2009 Aug; 5(8):536-44.
    View in: PubMed
    Score: 0.003
  44. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA. 2008 Oct 01; 300(13):1532-43.
    View in: PubMed
    Score: 0.003
  45. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis. 2006 Nov 01; 43(9):1135-42.
    View in: PubMed
    Score: 0.003
  46. 5' dinucleotide repeat polymorphism of NRAMP1 and susceptibility to tuberculosis among Caucasian patients in Houston, Texas. Int J Tuberc Lung Dis. 2002 Sep; 6(9):818-23.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.